|Bid||61.02 x 900|
|Ask||61.03 x 800|
|Day's range||60.36 - 61.24|
|52-week range||56.75 - 69.75|
|Beta (5Y monthly)||0.59|
|PE ratio (TTM)||N/A|
|Earnings date||27 Oct 2021|
|Forward dividend & yield||1.96 (3.16%)|
|Ex-dividend date||30 Sep 2021|
|1y target est||80.24|
PRINCETON, N.J., September 17, 2021--BMS Receives Positive CHMP Opinion for Opdivo + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal....
In the latest trading session, Bristol Myers Squibb (BMY) closed at $61.23, marking a -1.24% move from the previous day.
PRINCETON, N.J., September 16, 2021--Five-Year Data from CheckMate -214 Show Opdivo Plus Yervoy Demonstrates Longest Median Overall Survival Currently Reported in Phase 3 Trial.....